Effects Of Semaglutide Across The Range Of Left Ventricular Ejection Fraction In Obesity Phenotype Of Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Trial
Javed Butler,Sanjiv J. Shah,Steen Z. Abildstrøm,Rebecca Lynn Altschul,Barry A. Borlaug,Melanie J. Davies,G. Kees Hovingh,Dalane W. Kitzman,Daniél V. Møller,Mark C. Petrie,Søren Rasmussen,Subodh Verma,Mikhail N. Kosiborod
DOI: https://doi.org/10.1016/j.cardfail.2023.10.465
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background STEP-HFpEF, a 52 week trial conducted in patients with obesity phenotype of heart failure with preserved ejection fraction (HFpEF) and no type 2 diabetes, examined the effects of once-weekly semaglutide 2.4 mg versus placebo on HF-related symptoms, physical limitations, and exercise function, as well as inflammation and body weight (BW). Except for sodium-glucose co-transporter 2 inhibitors, previous HF therapies have shown differential effects across the spectrum of left ventricular ejection fraction (LVEF). In this pre-specified analysis, we investigated the effects of semaglutide on the primary and key secondary endpoints across the range of LVEF in the STEP-HFpEF Trial. Methods STEP-HFpEF randomized 529 participants with symptomatic HF, LVEF ≥45% and body mass index of ≥30 kg/m2 to receive once weekly semaglutide 2.4 mg or placebo. Key exclusion criteria were prior or planned bariatric surgery, self-reported change in BW >11 pounds (5 kilograms) within 90 days prior to randomization, and a HbA1c level ≥6.5% or prior medical history of diabetes. Dual primary endpoints were change from baseline in Kansas City Cardiomyopathy Questionnaire Clinical Score (KCCQ-CSS) and BW. Confirmatory secondary endpoints included change in 6-minute walk distance (6MWD), hierarchical composite endpoint (death, HF events and change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP). For this analysis, patients were stratified based on baseline LVEF of 45-49%, 50-59%, and ≥60%. The effects of semaglutide versus placebo on the dual primary and confirmatory secondary endpoints were examined across these LVEF categories. Results Overall, the median LVEF in STEP-HFpEF was 57%; 16.1, 40.6, and 43.3% of participants had LVEF of 45-49%, 50-59%, and ≥60%, respectively. Baseline characteristics of patients in the three LVEF based sub-groups are shown in the Table. The effects of semaglutide compared with placebo on the dual primary and confirmatory secondary outcomes across these LVEF categories will be presented. Conclusions STEP-HFpEF is the first clinical trial of pharmacotherapy to specifically target the obesity phenotype of HFpEF. In this pre-specified analysis, we will examine whether the effects of semaglutide on symptoms, physical limitations, exercise function, as well as inflammation and BW in this patient population are consistent across the range of LVEF.
cardiac & cardiovascular systems